Regeneron’s trial shows semaglutide combos improve fat loss while preserving muscle in obesity treatment. Read more here.

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Scientists found brain cells behind semaglutide’s weight-loss power—and they don’t cause the nasty side effects.

As the Food and Drug Administration clamps down on off-brand weight loss medications, Seattle-area residents are stocking up ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Perspective from Sangeeta Kashyap, MD Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, according to findings from the ...

A major 72-week trial shows tirzepatide leads to double-digit weight loss and greater waist reduction than semaglutide ... practice rather than a fixed-dose protocol. Among the 750 enrolled ...

If tirzepatide can’t be accessed, semaglutide is still a good choice because 15% weight loss, particularly at the population level, is enormous. “Ten years ago, if someone had told you semaglutide was ...

Metamorphx is emerging as a leading natural GLP-1 alternative for weight loss in 2025. With prescription options like semaglutide ... any new supplement protocol. Who Should Avoid Metamorphx?

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide is the active ingredient in the weight loss medication Wegovy and the diabetes drugs Ozempic and Rybelsus, which are ...

It further argues that the trial’s “flexible protocol,” which allowed patients to adjust their dosage, hampered the study’s ability to accurately assess weight loss at the tested dosage.

The 48-week Phase 2 study at the highest dose demonstrated the mean weight loss was 24.2% of body weight, which was completed in 2023. The Phase 3 study could result in 25 to 30% mean weight loss.